Krystal Biotech, Inc. KRYS
Set alert
282.52 USD -49.77 -14.98%
As of Nov 2, 11:30 AM ET
281.82 Day range 315.35
184.02 52-week range 382.54
- YTD
- +14.59%
- 1 year
- +43.04%
- Open
- 314.21
- Prev close
- 332.29
- Mkt cap
- 8.36B
- Vol
- 483.77K
- Avg vol
- 272.35K
- EPS
- 7.98
- P/E
- 35.40
- Div yield
- 0.00%
More statistics
- Low
- 281.82
- High
- 315.35
- Forward P/E
- 37.12
- Beta
- 0.50
- Short ratio
- 9.85
- Inst. own
- 102.62%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 2, 2026
- 50-d avg
- 337.56
- 200-d avg
- 308.33
- 1y target
- 395.44
6M chart
Events in this range
- May 4, 2026Earnings: 1.83; estimate 1.45; surprise 26.21%
- Jun 18, 2026Rating: TD Cowen · Buy → Buy
- Jul 14, 2026Rating: B of A Securities · Buy → Buy
- Aug 3, 2026Earnings: 1.79; estimate 1.7; surprise 5.29%
- Aug 4, 2026Rating: Citigroup · Buy → Buy
- Aug 14, 2026Rating: RBC Capital · — → Outperform
- Sep 21, 2026Rating: B of A Securities · Buy → Buy
- Oct 15, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Nov 2, 2026Earnings: —; estimate 1.79; surprise —%
Signals (28)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Nov 2, 2026 | 2 hours ago |
| MACD: Buy Signal | Oct 28, 2026 | 5 days ago |
| MACD: Sell Signal | Oct 16, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 15, 2026 | 2 weeks ago |
| SMA: Bearish | Sep 29, 2026 | 1 month ago |
| SMA: Bearish | Sep 28, 2026 | 1 month ago |
| SMA: Bullish | Sep 24, 2026 | 1 month ago |
| SMA: Bearish | Sep 23, 2026 | 1 month ago |
| SMA: Bullish | Sep 22, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 10, 2026 | 1 month ago |
| SMA: Bearish | Sep 9, 2026 | 1 month ago |
| SMA: Bullish | Aug 25, 2026 | 2 months ago |
| SMA: Bearish | Aug 24, 2026 | 2 months ago |
| SMA: Bullish | Aug 21, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 18, 2026 | 2 months ago |
| SMA: Bearish | Aug 3, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 31, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 30, 2026 | 3 months ago |
| SMA: Bullish | Jul 24, 2026 | 3 months ago |
| SMA: Bearish | Jul 23, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 10, 2026 | 3 months ago |
| RSI: Overbought | Jul 8, 2026 | 3 months ago |
| RSI: Overbought | Jun 25, 2026 | 4 months ago |
| RSI: Overbought | Jun 17, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 11, 2026 | 4 months ago |
| MACD: Sell Signal | May 20, 2026 | 5 months ago |
| RSI: Overbought | May 8, 2026 | 5 months ago |
| MACD: Buy Signal | May 4, 2026 | 6 months ago |
Key statistics
- Market cap
- 9.84B
- Enterprise value
- 8.77B
- Trailing P/E
- 41.64
- Forward P/E
- 37.12
- PEG ratio
- 0.00
- Price / sales
- 22.33
- Price / book
- 7.24
- EPS (TTM)
- 7.98
- Beta
- 0.50
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 54.82%
- Revenue (TTM)
- 440.48M
- Revenue growth
- 24.10%
- Free cash flow
- 151.74M
- Total cash
- 845.63M
- Total debt
- 8.85M
- Return on equity
- 20.12%
- Shares outstanding
- 29.60M
- Short % of float
- 16.24%
- 50-day average
- 337.56
- 200-day average
- 308.33
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 395.44 +40.0% upside
Now 282.52
- Target (low)
- 284.00
- Target (mean)
- 395.44
- Target (high)
- 474.00
Ratings (0m) 12 11 buy · 1 hold · 0 sell
- Strong buy1
- Buy10
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 2, 2026
Expected Nov 2, 2026. Consensus EPS estimate 1.92.
Financials — quick view
KRYS Revenue — quarterly 119.22M
KRYS Net income — quarterly 54.77M
KRYS EPS — quarterly 1.85
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 2, 2026 | Sep 30, 2026 | 1.79 | — | — | — |
| Aug 3, 2026 | Jun 30, 2026 | 1.70 | 1.79 | +0.09 | +5.29% |
| May 4, 2026 | Mar 31, 2026 | 1.45 | 1.83 | +0.38 | +26.21% |
| Feb 17, 2026 | Dec 31, 2025 | 1.62 | 1.70 | +0.08 | +4.94% |
| Nov 3, 2025 | Sep 30, 2025 | 1.12 | 2.66 | +1.54 | +137.50% |
| Aug 4, 2025 | Jun 30, 2025 | 1.08 | 1.29 | +0.21 | +19.44% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 15, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 21, 2026 | B of A Securities | main | Buy | Buy |
| Aug 14, 2026 | RBC Capital | init | — | Outperform |
| Aug 4, 2026 | Citigroup | main | Buy | Buy |
| Jul 14, 2026 | B of A Securities | main | Buy | Buy |
| Jun 18, 2026 | TD Cowen | main | Buy | Buy |
About Krystal Biotech, Inc.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- krystalbio.com
News
- Krystal Biotech Q3 2026 Earnings Call Transcript
- Krystal Biotech Q3 EPS $2.05 Beats $1.77 Estimate, Sales $127.341M Beat $126.079M Estimate
- Krystal Biotech Announces Third Quarter 2026 Financial and Operating Results
- Apple, Palantir On Deck Monday As AI Demand, iPhone Growth Face Test
- Analysts Estimate Krystal Biotech, Inc. (KRYS) to Report a Decline in Earnings: What to Look Out for
- Here's How Much $100 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today
- Krystal Biotech to Report Third Quarter 2026 Financial Results on November 2, 2026
- KRYS Reports Positive Early Data for KB113 in Gorlin Syndrome
- HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $361 Price Target
- Krystal Biotech Reports Over 80% Lesion Reduction in Rare Skin Cancer Trial
Your note
Sign in to keep a note on KRYS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| JANNEY DANIEL SPENCER | Director | Sale | Feb 26, 2026 | 0 |
| KRISHNAN KRISH S | Chief Executive Officer | Sale | Sep 3, 2026 | 1,565,250 |
| KRISHNAN SUMA M | Officer, Director and Beneficial Owner | Sale | Sep 3, 2026 | 1,493,160 |
| ROMANO KATHRYN | Officer | Sale | Mar 1, 2026 | 22,366 |
| ROSSI DINO A | Director | Stock Gift | Aug 13, 2026 | 50,000 |
| THOMAS JOHN CHARLES MICHAEL | General Counsel | Sale | Jun 24, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.93% | 4,418,197 | 1.47B | Jun 29, 2026 |
| Blackrock Inc. | 14.13% | 4,181,432 | 1.39B | Jun 29, 2026 |
| Avoro Capital Advisors LLC | 9.76% | 2,888,888 | 959.95M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 5.32% | 1,574,905 | 523.33M | Jun 29, 2026 |
| State Street Corporation | 4.56% | 1,351,158 | 448.98M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.19% | 1,240,567 | 412.23M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 6.09% | 1,802,622 | 598.99M | Aug 30, 2026 |
| iShares Trust-iShares Core S&P Mid-Cap ETF | 3.21% | 948,897 | 315.31M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.01% | 889,548 | 295.59M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 2.76% | 816,132 | 271.19M | Aug 30, 2026 |
| SmallCap World Fund Inc | 2.54% | 752,244 | 249.96M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.28% | 675,066 | 224.32M | Sep 29, 2026 |